Insider Trading activities of Cara Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cara Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cara Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Cara Therapeutics, Inc. since 2005. The reporting company's ticker symbol is CARA. The reporting company's CIK number is 1346830.
The total value of stock buying since 2005 is $19,306,299.
The total value of stock sales since 2005 is $11,611,920.
The total value of stock option exercises since 2005 is $187,469.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Cara Therapeutics, Inc. (CARA).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 0 $0 16,000 $202,560 40,000 $99,200
2017-08 0 $0 3,000 $45,000 0 $0
2017-07 0 $0 28,000 $421,250 14,000 $33,800
2017-06 0 $0 250,000 $6,548,750 0 $0
2017-03 500,000 $9,095,500 0 $0 0 $0
2016-04 0 $0 6,000 $54,000 0 $0
2016-03 800,000 $3,898,316 0 $0 28,000 $39,469
2016-02 0 $0 6,000 $54,250 0 $0
2016-01 0 $0 56,986 $926,543 0 $0
2015-12 0 $0 18,776 $314,452 0 $0
2015-11 0 $0 6,000 $85,560 0 $0
2015-10 0 $0 6,000 $84,690 0 $0
2015-09 0 $0 7,000 $130,410 0 $0
2015-08 5,000 $103,500 7,000 $149,870 0 $0
2015-07 0 $0 14,262 $170,214 0 $0
2015-06 0 $0 7,262 $68,989 0 $0
2015-05 0 $0 196,073 $1,968,694 0 $0
2015-04 0 $0 7,262 $71,893 0 $0
2015-03 0 $0 7,262 $73,418 20,000 $5,000
2015-02 0 $0 22,262 $241,377 0 $0
2014-08 0 $0 0 $0 40,000 $10,000
2014-02 564,453 $6,208,983 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Cara Therapeutics, Inc. insiders (CARA)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-07 Menzaghi Frederique Ph.d. (Sr VP-Research & Development) Option Ex 20,000 2.48 49,600
2017-11-03 Chalmers Derek T (President & CEO) Option Ex 20,000 2.48 49,600
2017-11-01 Chalmers Derek T (President & CEO) Sale 16,000 12.66 202,560
2017-08-04 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 3,000 15.00 45,000
2017-07-26 Schoell Josef (Chief Financial Officer) Option Ex 4,000 2.25 9,000
2017-07-14 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 3,000 15.00 45,000
2017-07-14 Chalmers Derek T (President & CEO) Sale 25,000 15.05 376,250
2017-07-14 Chalmers Derek T (President & CEO) Option Ex 10,000 2.48 24,800
2017-06-29 Slagel Dean (Director) Sale 250,000 26.20 6,548,750
2017-03-31 Ruch Joshua Buy 500,000 18.19 9,095,500
2016-04-20 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 6,000 9.00 54,000
2016-03-17 Vogelbaum Martin Buy 247,727 4.93 1,221,294
2016-03-17 Kairouz Habib Buy 247,727 4.93 1,221,294
2016-03-16 Schoell Josef (Chief Financial Officer) Option Ex 18,000 .81 14,669
2016-03-16 Vogelbaum Martin Buy 152,273 4.78 727,864
2016-03-16 Kairouz Habib Buy 152,273 4.78 727,864
2016-03-15 Chalmers Derek T (President & CEO) Option Ex 10,000 2.48 24,800
2016-02-03 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 1,000 9.00 9,000
2016-02-01 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 5,000 9.05 45,250
2016-01-26 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 10.93 79,373
2016-01-06 Chalmers Derek T (President & CEO) Sale 12,500 17.22 215,250
2016-01-05 Slagel Dean (Director) Sale 31,224 17.01 531,120
2016-01-04 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 6,000 16.80 100,800
2015-12-31 Slagel Dean (Director) Sale 12,776 17.00 217,192
2015-12-01 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 6,000 16.21 97,260
2015-11-02 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 6,000 14.26 85,560
2015-10-01 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 6,000 14.12 84,690
2015-09-01 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 7,000 18.63 130,410
2015-08-18 Schoell Josef (Chief Financial Officer) Buy 3,000 22.10 66,300
2015-08-04 Stauffer Joseph William (Chief Medical Officer) Buy 2,000 18.60 37,200
2015-08-03 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 7,000 21.41 149,870
2015-07-01 Menzaghi Frederique Ph.d. (VP-Research & Development) Sale 7,000 12.22 85,540
2015-07-01 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 11.66 84,674
2015-06-01 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 9.50 68,989
2015-05-19 Slagel Dean (Director) Sale 32,266 10.00 322,660
2015-05-18 Slagel Dean (Director) Sale 82,945 10.04 832,767
2015-05-15 Slagel Dean (Director) Sale 73,600 10.00 736,000
2015-05-01 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 10.64 77,267
2015-04-01 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 9.90 71,893
2015-03-09 Menzaghi Frederique Ph.d. (VP-Research & Development) Option Ex 20,000 .25 5,000
2015-03-02 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 10.11 73,418
2015-02-17 Schoell Josef (Chief Financial Officer) Sale 15,000 10.96 164,400
2015-02-02 Lewis Michael E (Chief Scientific Advisor) Sale 7,262 10.60 76,977
2014-08-14 Schoell Josef (Chief Financial Officer) Option Ex 40,000 .25 10,000
2014-02-05 Vogelbaum Martin (Director) Buy 225,818 11.00 2,483,998
2014-02-05 Penhoet Edward (10% Owner) Buy 112,817 11.00 1,240,987
2014-02-05 Ruch Joshua (10% Owner) Buy 225,818 11.00 2,483,998

Insider trading activities including stock purchases, stock sales, and option exercises of CARA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cara Therapeutics, Inc. (symbol CARA, CIK number 1346830) see the Securities and Exchange Commission (SEC) website.